These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 19729997)

  • 1. Target-based agents in neoadjuvant treatment of liver metastases from colorectal cancer: secret weapons in anti-cancer war?
    Marra M; Giudice A; Arra C; Vitale G; Castiglioni S; Nasti G; Lombardi A; Ottaiano A; Facchini G; Iaffaioli RV; Abbruzzese A; Caraglia M
    Cancer Biol Ther; 2009 Sep; 8(18):1709-18. PubMed ID: 19729997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab.
    Yoo PS; Lopez-Soler RI; Longo WE; Cha CH
    Clin Colorectal Cancer; 2006 Sep; 6(3):202-7. PubMed ID: 17026789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histological response, pattern of tumor destruction and clinical outcome after neoadjuvant chemotherapy including bevacizumab or cetuximab in patients undergoing liver resection for colorectal liver metastases.
    Stremitzer S; Stift J; Singh J; Starlinger P; Gruenberger B; Tamandl D; Gruenberger T
    Eur J Surg Oncol; 2015 Jul; 41(7):868-74. PubMed ID: 25865557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis.
    Ji JH; Park SH; Lee J; Kim TW; Hong YS; Kim KP; Kim SY; Baek JY; Kang HJ; Shin SJ; Shim BY; Park YS
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):223-30. PubMed ID: 23689915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Choice of surgical strategy for colorectal liver metastases depending on clinical and pathological response to neoadjuvant chemo- and targeted therapy].
    Jakab F
    Orv Hetil; 2010 Nov; 151(47):1956-60. PubMed ID: 21071308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Recent results of irinotecan therapy in colorectal cancer].
    Láng I; Hitre E
    Magy Onkol; 2004; 48(4):281-8. PubMed ID: 15655572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab.
    Ellis LM; Curley SA; Grothey A
    J Clin Oncol; 2005 Aug; 23(22):4853-5. PubMed ID: 16051943
    [No Abstract]   [Full Text] [Related]  

  • 8. Pathologic complete response to neoadjuvant FOLFOX in combination with bevacizumab in unresectable metastatic colorectal carcinoma.
    Duffy A; Shia J; Huitzil-Melendez FD; Fong Y; O'Reilly EM
    Clin Colorectal Cancer; 2008 Mar; 7(2):140-3. PubMed ID: 18501074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.
    Asseburg C; Frank M; Köhne CH; Hartmann JT; Griebsch I; Mohr A; Osowski U; Schulten J; Mittendorf T
    Clin Ther; 2011 Apr; 33(4):482-97. PubMed ID: 21635994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coexpression of biological key modulators in primary colorectal carcinomas and related metastatic sites: implications for treatment with cetuximab.
    Barbier A; Domont J; Magné N; Goldmard JL; Genestie C; Hannoun C; Vaillant JC; Bellanger A; Khayat D; Capron F; Spano JP
    Bull Cancer; 2010 Feb; 97(2):E9-E15. PubMed ID: 20085858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversal of attachment to or invasion of major intrahepatic vessels by colorectal liver metastases according to prehepatectomy chemotherapy regimen.
    Tanaka K; Nakagawa K; Yabushita Y; Hiroshima Y; Matsuo K; Ota M; Ichikawa Y; Taguri M; Tanabe M; Koda K; Endo I
    Surgery; 2014 May; 155(5):936-44. PubMed ID: 24656858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver resection remains a safe procedure after neoadjuvant chemotherapy including bevacizumab: a case-controlled study.
    Tamandl D; Gruenberger B; Klinger M; Herberger B; Kaczirek K; Fleischmann E; Gruenberger T
    Ann Surg; 2010 Jul; 252(1):124-30. PubMed ID: 20562613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases.
    Pietrantonio F; Mazzaferro V; Miceli R; Cotsoglou C; Melotti F; Fanetti G; Perrone F; Biondani P; Muscarà C; Di Bartolomeo M; Coppa J; Maggi C; Milione M; Tamborini E; de Braud F
    Med Oncol; 2015 Jul; 32(7):182. PubMed ID: 26003673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bevacizumab-based neoadjuvant chemotherapy for colorectal cancer liver metastases: Pitfalls and helpful tricks in a review for clinicians.
    Pietrantonio F; Orlandi A; Inno A; Da Prat V; Spada D; Iaculli A; Di Bartolomeo M; Morosi C; de Braud F
    Crit Rev Oncol Hematol; 2015 Sep; 95(3):272-81. PubMed ID: 25958297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integration of novel agents in the treatment of colorectal cancer.
    Iqbal S; Lenz HJ
    Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New drugs for colorectal cancer].
    Pestalozzi BC; Jäger D; Knuth A
    Praxis (Bern 1994); 2004 Sep; 93(36):1455-9. PubMed ID: 15487860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complete resection of unresectable liver metastases from colorectal cancer without deterioration of liver function after cetuximab and irinotecan: two case reports.
    Karasaki T; Sano K; Takamoto T; Kinoshita H; Tateishi R; Takemura T; Makuuchi M
    Hepatogastroenterology; 2010; 57(104):1526-8. PubMed ID: 21443115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The COMET Open-label Phase II Study of Neoadjuvant FOLFOX or XELOX Treatment Combined with Molecular Targeting Monoclonal Antibodies in Patients with Resectable Liver Metastasis of Colorectal Cancer.
    Kataoka M; Kanda M; Ishigure K; Matsuoka H; Sato Y; Takahashi T; Tanaka C; Deguchi T; Shibata Y; Sato M; Inagaki H; Matsui T; Kondo A; Takano N; Tanaka H; Sakamoto J; Oba K; Kondo K
    Ann Surg Oncol; 2017 Feb; 24(2):546-553. PubMed ID: 27638675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effective second-line treatment with cetuximab and bevacizumab in a patient with hepatic metastases of colorectal cancer and hyperbilirubinemia.
    Moosmann N; Laessig D; Michaely HJ; Schulz C; Heinemann V
    Onkologie; 2007 Oct; 30(10):509-12. PubMed ID: 17890890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant therapy of bevacizumab in combination with oxaliplatin and capecitabine (XELOX) for patients with metastatic colorectal cancer with unresectable liver metastases: a phase II, open-label, single-arm, noncomparative trial.
    Chen HH; Lin JK; Chen JB; Chuang CH; Liu MC; Wang JY; Changchien CR
    Asia Pac J Clin Oncol; 2018 Feb; 14(1):61-68. PubMed ID: 28906589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.